IPP Bureau
Pfizer INDovation program boosts six start-ups with Rs. 1.5 crore grant
By IPP Bureau - November 11, 2024
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI
By IPP Bureau - November 11, 2024
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Granules India’s Unit V facility secures USFDA EIR with NAI status
By IPP Bureau - November 10, 2024
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
By IPP Bureau - November 10, 2024
Q2 FY25 Total Income was at Rs. 85.4 crore
Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr
By IPP Bureau - November 10, 2024
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics
By IPP Bureau - November 10, 2024
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
.jpg "DuPont launches Tyvek to support sustainable healthcare packaging")
DuPont launches Tyvek to support sustainable healthcare packaging
By IPP Bureau - November 09, 2024
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Lupin receives tentative approval from USFDA for Raltegravir Tablets
By IPP Bureau - November 09, 2024
This product will be manufactured at Lupin’s Nagpur facility in India
K J Somaiya Hospital & Research Centre launches advanced neurosciences centre in Mumbai
By IPP Bureau - November 08, 2024
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr
By IPP Bureau - November 08, 2024
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
Abbott India reports Q2 FY25 standalone PAT at Rs. 358.61 Cr
By IPP Bureau - November 08, 2024
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Medanta to operate and manage 750 bed super speciality hospital in Pitampura, New Delhi
By IPP Bureau - November 08, 2024
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Neuland Laboratories Q2 FY25 consolidated PAT falls to Rs. 32.84 Cr
By IPP Bureau - November 08, 2024
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
By IPP Bureau - November 07, 2024
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
